Savara Inc. (Nasdaq: SVRA) will present significant research findings on autoimmune pulmonary alveolar proteinosis (aPAP) at the upcoming European Respiratory Society (ERS) Congress 2025. The congress is scheduled to take place from September 27 to October 1, 2025, in Amsterdam, The Netherlands. Three of Savara’s abstracts have been accepted for poster presentation, highlighting the company’s commitment to advancing understanding and treatment of this rare lung disease.
Key Research Highlights
The research presentations will cover critical aspects of aPAP, including disease burden, treatment efficacy, and diagnostic advancements.
One study, led by Dr. Francesco Bonella from Ruhrlandklinik University Hospital, delves into the relationship between pulmonary gas transfer and the overall quality of life for patients suffering from aPAP. This research will explore how factors such as exercise capacity and surfactant burden impact respiratory health.
Another presentation by Dr. Cormac McCarthy from University College Dublin will examine the efficacy of inhaled molgramostim, particularly across various levels of disease severity. This study aims to provide insights into the potential benefits of this treatment option for patients.
Additionally, Dr. Eagappanath Thiruppathi from TrilliumBiO will introduce a novel dried serum assay designed to detect GM-CSF antibodies. This tool aims to enhance diagnostic accuracy for aPAP, addressing a critical need for improved diagnostic methods.
Mini Symposium on aPAP Advances
Savara will host an Industry Evening Mini Symposium on September 29, titled “Advances in Autoimmune Pulmonary Alveolar Proteinosis.” The session will feature presentations on the pathophysiology of the disease, its signs and symptoms, the burden of illness, and evolving treatment strategies.
Key presenters include Dr. Effrosyni D. Manali from the National and Kapodistrian University of Athens, Dr. Maria Molina-Molina from Hospital Universitario de Bellvitge in Spain, and Dr. Maria Kokosi from Royal Brompton Hospital in London. The session will be chaired by Brian Robinson, M.D., Executive Vice President of Global Medical Affairs at Savara.
By showcasing these studies and facilitating discussions at ERS 2025, Savara aims to enhance awareness and understanding of autoimmune pulmonary alveolar proteinosis. The company’s research underscores its dedication to improving diagnostics and treatment strategies for patients affected by this rare and often misunderstood condition.
